Assessing the Likely Cost-Utility of Alemtuzumab Versus Rabbit Anti-Thymocte Globulin as Induction Therapy for High-Risk Kidney Transplant Recipients

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.1709
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Poor Outcomes in Elderly Kidney Transplant Recipients Receiving Alemtuzumab Induction

American Journal of Nephrology
Nephrology
2011English

Daclizumab Versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2009English

Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-Il2 Receptor Monoclonal Antibodies?

American Journal of Transplantation
TransplantationAllergyImmunologyPharmacology
2016English

Serum Sickness After Treatment With Rabbit Antithymocyte Globulin in Kidney Transplant Recipients With Previous Rabbit Exposure

American Journal of Kidney Diseases
Nephrology
2010English

Correction To: Basiliximab Versus Rabbit Antithymocyte Globulin as Induction Therapy for Living-Related Renal Transplantation: A Single-Center Experience

International Urology and Nephrology
UrologyNephrology
2019English

Impact of Protease Inhibitor Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant Recipients

American Journal of Transplantation
TransplantationAllergyImmunologyPharmacology
2017English

PUK20 Cost-Utility Assessment of Sirolimus Versus Tacrolimus for Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

The Influence of Induction Therapy for Kidney Transplantation After a Non-Renal Transplant

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2011English

Safety Events in Kidney Transplant Recipients

Transplantation
Transplantation
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy